Paul Kim Acquires 100,000 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT - Get Free Report) CFO Paul Kim acquired 100,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the acquisition, the chief financial officer now owns 348,282 shares in the company, valued at $5,558,580.72. This trade represents a 40.28 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Fulgent Genetics Trading Up 3.9 %

Shares of FLGT stock traded up $0.69 during mid-day trading on Friday, reaching $18.59. The stock had a trading volume of 813,378 shares, compared to its average volume of 202,224. The stock's 50-day moving average price is $17.14 and its two-hundred day moving average price is $19.23. Fulgent Genetics, Inc. has a 52-week low of $14.57 and a 52-week high of $25.11. The firm has a market capitalization of $573.11 million, a PE ratio of -3.37 and a beta of 1.54.

Hedge Funds Weigh In On Fulgent Genetics

A number of hedge funds have recently modified their holdings of the company. GAMMA Investing LLC increased its position in shares of Fulgent Genetics by 45.5% during the fourth quarter. GAMMA Investing LLC now owns 2,133 shares of the company's stock valued at $39,000 after buying an additional 667 shares during the period. Point72 DIFC Ltd purchased a new position in shares of Fulgent Genetics during the third quarter valued at about $46,000. Russell Investments Group Ltd. increased its position in shares of Fulgent Genetics by 267.4% during the fourth quarter. Russell Investments Group Ltd. now owns 2,693 shares of the company's stock valued at $50,000 after buying an additional 1,960 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Fulgent Genetics during the fourth quarter valued at about $57,000. Finally, State of Wyoming purchased a new position in shares of Fulgent Genetics during the fourth quarter valued at about $57,000. Hedge funds and other institutional investors own 48.06% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

FLGT has been the subject of several analyst reports. StockNews.com raised shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a report on Wednesday. Piper Sandler dropped their price objective on shares of Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating for the company in a report on Tuesday.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.